Five major U.S. cannabis companies are carrying a combined $2 billion in uncertain tax liabilities, according to The Marijuana Herald's review of their latest SEC filings: Trulieve, Curaleaf, Verano, Ascend Wellness and Vireo Growth.
The backstory is Section 280E, the tax rule that blocks businesses dealing in Schedule I or II drugs from deducting normal costs like rent and salaries. Medical cannabis under state licenses moved to Schedule III on April 28, which takes those medical sales out of 280E. Recreational cannabis is still in Schedule I.
In April, Treasury and the IRS said upcoming guidance would generally let qualifying businesses claim relief for the whole tax year. That formal guidance still isn't out, so companies are making their own calls:
- Trulieve is recognizing relief for all of 2026 and reports $625.4 million in net uncertain tax liabilities.
- Curaleaf reports $476.1 million and is recognizing relief only from April 28, saying the IRS announcement "does not constitute authoritative guidance."
- Vireo is recognizing relief from April 23.
Curaleaf also disclosed that the IRS is examining some of its 2020–2024 returns.
What it means for travelers: You won't see this at the register right away. But how the tax relief shakes out could affect how much room big operators have on prices.






